Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

The safety and efficacy of immune checkpoint inhibitor in combination with FOLFOX as neoadjuvant/adjuvant therapy in patients with locally advanced colon cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

CCChangjing CaiYHYing HanYPYinghui Peng

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cai et al. (2024) studied this question.

synapsesocial.com/papers/68e67054b6db6435875fa98fhttps://doi.org/10.1200/jco.2024.42.16_suppl.e15621
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant combination versus single-agent immune checkpoint inhibition in locally advanced MSI-H/dMMR colorectal cancer: A systematic review and meta-analysis.2026
  2. 2Neoadjuvant immunotherapy combined with radiochemotherapy vs chemotherapy alone in pMMR colon cancers: The TORCH-C randomized phase 2 clinical trial.2026
  3. 3Neoadjuvant tislelizumab plus chemotherapy in MSS/pMMR high-risk locally advanced colon cancer: Updated analysis results from a phase 2 trial.2026
  4. 4Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer2024 · 15 citations
  5. 5Neoadjuvant chemotherapy versus surgery plus adjuvant chemotherapy for locally advanced colon cancer: A meta-analysis of randomized controlled trials.2024